Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861705 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 454
- Enrollment target
NCT00861705: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00861705 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 454 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861705, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 454 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2009-07-21 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00861705
The ClinicalTrials.gov registry entry for NCT00861705 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00861705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00861705 about?
NCT00861705 is a clinical study titled "Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery". This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubici...
What is the current status of trial NCT00861705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 454 participants. The study started on 2009-07-21. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT00861705?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00861705?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.